摘要
目的观察尿激酶与低分子肝素钙联用治疗急性心肌梗死的临床疗效。方法选取我院从2002年1月至2012年12月所收治的120例急性心肌梗死患者作为临床研究对象,并将所有患者随机分为治疗组和对照组两组各60例。两组均进行严密心电检查、吸氧、绝对卧床休息、硝酸酯类药物、ACEI药物和服用肠溶阿司匹林等,治疗组在此基础上加用尿激酶和低分子肝素钙进行治疗。观察两组患者的急性期心脏事件发生情况和冠状动脉再通情况,以综合考察两组疗效。结果两组患者在梗死后心绞痛、心力衰竭和死亡率的差异均有统计学意义,治疗组显著低于对照组(P<0.05)。治疗组冠状动脉再通率为63.3%,对照组冠状动脉再通率为26.7%,两组冠状动脉再通率比较,差异有统计学意义(P<0.05)。结论尿激酶与低分子肝素钙联合应用对急性心肌梗死患者的疗效显著,能提高患者的存活率和生活质量,值得在临床中推广应用。
Objective To observe the clinical effect of urokinase combined with low-molecular-weight heparin in the treatment of acute myocardial infarction.Methods 120 patients with acute myocardial infarction in our hospital from January 2002 to December 2012 were selected and randomly divided into the treatment group and control group,with 60 cases in each group.All patients received the ECG examination,oxygen,absolute bed rest,and drugs with nitrates,ACEI and enteric-coated aspirin,and patients in the treatment group received the extra combination treatment with urokinase and low-molecular-weight heparin.The cardiac events and coronary artery recanalization of two groups were observed to evaluate the clinical treatment effect.Results The treatment group had lower postinfarctional angina pectoris events,heart failure events and mortality compared with the control group,and the differences were statistically significant（P 0.05）.The coronary artery recanalization rate was 63.3% in the treatment group and 26.7% in the control group,and the differences were statistically significant（P 0.05）.Conclusions Urokinase combined with low-molecular-weight heparin in the treatment of acute myocardial infarction has significant curative effect.It can improve patients＇ survival rate and quality of life,which is worthy of clinical application and promotion.
出处
《临床医学工程》
2013年第9期1125-1126,共2页
Clinical Medicine & Engineering
关键词
尿激酶
低分子肝素钙
急性心肌梗死
Urokinase
Low-molecular-weight heparin
Acute myocardial infarction
